Balyasny Asset Management
CTNM

Balyasny Asset Management’s Contineum Therapeutics CTNM Stock Holding History

Balyasny Asset Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22M Sell
1,685,635
-157,165
-9% -$2.11M 0.03% 648
2025
Q4 		$21.1M Buy
1,842,800
+891,480
+94% +$10.2M 0.03% 685
2025
Q3 		$11.2M Buy
+951,320
New +$7.67M 0.01% 995

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management's CTNM Position: Q1 2026 in Review

Balyasny Asset Management reduced its Contineum Therapeutics (CTNM) stake by 8.5% in Q1 2026, selling an estimated $2.11M and leaving 1,685,635 shares worth $22M. The position accounts for 0.03% of the portfolio, ranked #648.

Balyasny Asset Management first reported a position in CTNM in Q3 2025 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Balyasny Asset Management held 1,685,635 shares of Contineum Therapeutics worth $22M as of Q1 2026.
  • Balyasny Asset Management sold 157,165 Contineum Therapeutics shares in Q1 2026, an estimated $2.11M.
  • Contineum Therapeutics made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #648 holding.
  • Balyasny Asset Management first reported a position in Contineum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.